Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cytophage has developed a versatile bacteriophage-based antibacterial and antiviral technology targeting human and agricultural infectious diseases. With lead programs in avian and swine bacterial infections and in COVID-19, the company is seeking to expand its partnership network.
Biofilms are a major contributor to the global challenge of antibiotic resistance. BioFilm Control is leading the way in eradicating the biofilm barrier and overcoming antibiotic resistance with compounds that have blockbuster potential.
Protein engineering company Lytica Therapeutics is pioneering the use of α-helical stapled antimicrobial peptides (StAMPs) to lyse and kill multidrug-resistant bacteria.
Nosopharm is an innovative biotechnology company that is focused on exploring untapped microbial biodiversity to discover new drugs to fight antimicrobial resistance.
Forge Therapeutics has built a proprietary platform called MAGNET (Metalloprotein-targeting Approach to Generating New Experimental Therapeutics) to discover novel-class anti-infectives. With a development candidate to treat infections caused by high-priority Gram-negative pathogens, Forge is advancing its portfolio with partners worldwide.
We present a round up of selected biopharma, biotechnology and drug discovery stories published in September 2021 across the Springer Nature portfolio of journals.
We round up the key biopharma, biotechnology and drug discovery stories that were published in July and August 2021 across the Springer Nature portfolio of journals.
Next-generation immuno-oncology targets continue to catalyze major deals, exemplified by the race to develop inhibitors of the immune checkpoint TIGIT.
Precision medicine is at the heart of immunotherapy, yet the development of new immunotherapies is hampered by the lack of predictive biomarkers, access to NGS testing, and large prospective trials. Strata Oncology is addressing these challenges through an integrated platform.
Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B.
CyGenica Limited has developed a new class of engineered cell-penetrating protein as a drug delivery system, creating a drilling mechanism which can penetrate target cell membranes and safely deliver a range of cargoes including cancer drugs, antibiotics, gene therapy products and therapeutic nucleic acids.
MUVON Therapeutics has developed a patent-protected, GMP-compliant method for isolating and expanding muscle precursor cells that are injected into patients to promote regeneration of skeletal muscle, with an initial application in stress urinary incontinence.
Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.
Pennsylvania-based Geneos Therapeutics is using its clinically validated GT-EPIC platform to generate cancer immunotherapies with high neoantigen payloads, and more.
Trans-Atlantic biopharmaceutical company, Immatics, is poised to unlock and deliver innovative T cell-based therapies to cancer patients by harnessing two proprietary technology platforms for its own pipeline, and for collaborations with world-leading partners.
Actinium combines the precise targeting ability of monoclonal antibodies with the proven cancer-fighting power of radiation to develop innovative therapies for patients with cancers lacking effective treatment options.
